C12N 2710/10051
Methods of production or purification of viral material
C12N2710/10051 (Methods of production or purification of viral material) appears on 75 US grants and 138 published applications in this corpus.
Search patents in C12N- Granted patents
- 75
- Published applications
- 138
- Assignees
- 89
- Inventors
- 279
- Latest grant
- 18 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2001 | 1 | 0 |
| 2002 | 2 | 3 |
| 2003 | 0 | 7 |
| 2004 | 5 | 2 |
| 2005 | 3 | 10 |
| 2006 | 0 | 1 |
| 2007 | 4 | 3 |
| 2008 | 3 | 6 |
| 2009 | 3 | 6 |
| 2010 | 0 | 2 |
| 2011 | 4 | 1 |
| 2012 | 3 | 2 |
| 2013 | 2 | 9 |
| 2014 | 4 | 3 |
| 2015 | 4 | 9 |
| 2016 | 4 | 5 |
| 2017 | 3 | 4 |
| 2018 | 3 | 4 |
| 2019 | 4 | 4 |
| 2020 | 5 | 7 |
| 2021 | 4 | 6 |
| 2022 | 5 | 9 |
| 2023 | 1 | 6 |
| 2024 | 1 | 7 |
| 2025 | 5 | 16 |
| 2026 | 2 | 6 |
By publication year. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Engineered adenovirus vectors and uses thereof18 Aug 2026US 12,709,761 B2
- Methods and systems for manufacturing viral vectors6 Jan 2026US 12,516,349 B2Regeneron Pharmaceuticals, Inc.
- Fast and accurate three-plasmid oncolytic adenovirus recombinant packaging system Ad5MixPlus and application thereof29 Jul 2025US 12,371,670 B2Voncolytic Therapeutics Co., Ltd.
- Method for obtaining efficient viral vector-based compositions for vaccination or gene therapy8 Jul 2025US 12,350,375 B2Leukocare AG
- Exogenous gene expression in recombinant adenovirus for minimal impact on viral kinetics22 Apr 2025US 12,281,324 B2The Salk Institute for Biological Studies
- Engineered adenovirus vectors and uses thereof8 Oct 2026US 2026/0308629 A1
- Adenoviral vector vaccine, and preparation method and use thereof10 Sep 2026US 2026/0265702 A1Cansino Biologics Inc.
- Vaccine against respiratory syncytial virus infection13 Aug 2026US 2026/0232787 A1Westvac Biopharma Co., Ltd.
- Tet-r expression cassettes and cell lines16 Jul 2026US 2026/0201417 A1Cevec Pharmaceuticals GmbH
- Method for releasing viral vectors16 Apr 2026US 2026/0103730 A1PCI Biotech AS
Most cited
By later US patents
- Method for the production and purification of adenoviral vectors110US 6,194,191 B1Introgen Therapeutics, Inc. · 2001
- Methods for rapid PEG-modification of viral vectors, compositions for enhanced gene transduction, compositions with enhanced physical stability, and uses therefor90US 6,399,385 B1The Trustees of the University of Pennsylvania · 2002
- Complementing cell lines58US 6,974,695 B2Crucell Holland B. V. · 2005
- Purified adenoviral compositions53US 6,726,907 B1Introgen Therapeutics, Inc. · 2004
- Complementing cell lines49US 6,492,169 B1Crucell Holland B. V. · 2002